Article Text

other Versions

PDF
IVIG blocks complement deposition mediated by anti-GM1 antibodies in multifocal motor neuropathy
  1. N Yuki1,2,
  2. H Watanabe3,
  3. T Nakajima1,
  4. P J Späth4
  1. 1Department of Neurology, Niigata National Hospital, Niigata, Japan
  2. 2Department of Clinical Research, Niigata National Hospital, Niigata, Japan
  3. 3Department of Clinical Laboratory Unit, Niigata National Hospital, Niigata, Japan
  4. 4Department of Pharmacology, University of Bern, Bern, Switzerland
  1. Correspondence to Dr Yuki, Departments of Microbiology and Medicine, National University of Singapore, Blk MD4A, Level 5 Science Drive 2, 17597 Singapore; micyuki{at}nus.edu.sg

Abstract

Background The pathogenesis of multifocal motor neuropathy (MMN) has yet to be established. MMN patients often carry anti-GM1 IgM antibodies, suggesting an autoimmune process involving complement. Intravenous immunoglobulin (IVIG) is the first line treatment, but its action mechanism is unknown.

Objective To test whether anti-GM1 IgM antibodies in MMN sera activate complement, inducing and propagating the disease and whether IVIG inhibits complement activation, resulting in clinical improvement.

Methods Sera with anti-GM1 IgM but not IgG or IgA reactivity were obtained from 13 patients with MMN. We tested whether their anti-GM1 IgM antibodies produced complement component deposits on GM1-coated microtiter plates and whether IVIG blocks such deposition.

Results C1q, C4b, C3b and C5b-9 were deposited on GM1-coated wells. Their depositions were highly correlated with anti-GM1 IgM antibody titre. IVIG reduced the deposition of these complement components dose-dependently.

Conclusions Anti-GM1 IgM antibodies bound to GM1 and activated complement in vitro. The results together with earlier data from our group suggest that IgM-induced, complement-mediated injury occurs at the nodes of Ranvier in peripheral motor nerves and generates conduction block and muscle weakness. In vitro IVIG inhibited this type of complement activation, suggesting that in vivo, the resulting reduction in membrane attack complex-mediated damage leads to improved muscle strength.

  • Anti-GM1 antibody
  • complement
  • conduction block
  • intravenous immunoglobulin
  • multifocal motor neuropathy
  • ganglioside
  • guillain-barre syndrome
  • immunology
  • neuroimmunology
  • neuropathy

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the Dokkyo Medical University, Tochigi, Japan.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.